The investments come partly from a business angel network and a venture capital company that already owns shares in the company and partly from new financiers, each investing from some thousand SEK up to a couple of million SEK. In total, the company raised 6 million SEK for its continued international expansion.

Inhalation Science’s technology is today found among prominent players in the chemical and pharmaceutical sectors, where it is used to study how airborne particles impact the human body. In the autumn, the company received a breakthrough order in the US market from Dow Chemical, which uses the technology to study the risks in the development of new materials. In the pharmaceutical sector, the technology has been used for a couple of years by, among others, Chiesi, which is a leader in the development of inhalation drugs in Europe.

With the new capital, Inhalation Science will now increase the pace of expansion in the strongly growing markets for inhalation drugs and material development. In the spring, the company will raise additional capital ahead of the planned listing next year.

 

About Sciety

Sciety är en branschspecialiserad kapitalförmedlare som vill att innovationer inom life science ska nå sin fulla potential och skapa värde. Vill du få nyheter om aktuella bolag och inbjudningar till presentationer med bolagens ledning. Anmäl dig här.